Oruka Therapeutics files to sell 8.72M shares of common stock for holders
EST Oruka Therapeutics (ORKA) files to sell 8.72M shares of common stock for holders Published first on TheFly – the ultimate ...
Wedbush Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)
Wedbush analyst David Nierengarten maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today and set a price target of ...
manilatimes23h
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel ...
Oruka Therapeutics (ORKA) versus The Competition Critical Contrast
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka ...
Contrasting Oruka Therapeutics (ORKA) & The Competition
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...
Yahoo Finance6d
Oruka Therapeutics Inc. (HQ1.SG)
Research reports are not currently available for HQ1.SG.
Investing4d
Stifel sets $49 target on Oruka Therapeutics, cites innovation
On Thursday, Stifel, a financial services company, announced the initiation of coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating and a price target set at $49.00. The firm's positive ...
London South East6d
Oruka Therapeutics Inc Media
With our newsletters and social media channels.